2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.
Marc Humbert, Gabor Kovacs, Marius M Hoeper...
https://pubmed.ncbi.nlm.nih.gov/36017548/Actively Recruiting
Led by Azienda Ospedaliero-Universitaria Careggi · Updated on 2026-10-15
5000
Participants Needed
16
Research Sites
52 weeks
Total Duration
Researchers are conducting the PERSEUS Registry to observe adults diagnosed with acute pulmonary embolism PE. This registry collects detailed information from initial emergency response, emergency department visits, hospital stay including the first 48 hours of treatment, and long-term follow-up up to five years. The study aims to understand routine care approaches and outcomes such as mortality, disease complications, and how existing risk assessment tools perform in real-world settings. The study includes two groups a retrospective cohort with patients diagnosed from January 2023 until local ethics approval, and a prospective cohort enrolling newly diagnosed patients for five years following approval. Data collected include pre-hospital emergency care, hospital diagnostics and treatments, hemodynamic and respiratory changes during the acute phase, hospital discharge outcomes, and long-term follow-up through various contact methods or medical record review. Participants receive routine care without changes from the study. Information such as vital signs, imaging, laboratory tests, and clinical events are recorded. Follow-up assessments track survival, recurrence, bleeding events, functional limitations, and development of chronic complications. Data privacy is maintained with pseudonymization, and quality checks are regularly performed. The study continues until 2032, with primary outcomes focusing on mortality at 30 days after diagnosis.
CONDITIONS
Pulmonary Embolism Registry From Short-Term Emergency to Long-Term Follow-Up and Surveillance
S
Simone Vanni, MD, PhD
M
Matteo Gabriele Monda, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Azienda Ospedaliero-Universitaria Careggi
Lead Sponsor
University of Florence
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or record review)
Duration - From diagnosis until hospital discharge
Data are collected from pre-hospital emergency care, emergency department presentation, hospital stay including dynamic reassessments during the first 48 hours, and hospital discharge.
Regular clinical assessments as part of routine care
Duration - Up to 5 years
Participants are followed up at 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis to monitor survival, recurrence, bleeding events, functional status, and chronic complications.
In-person visits, telemedicine, telephone contacts, or clinical record reviews
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Marc Humbert, Gabor Kovacs, Marius M Hoeper...
https://pubmed.ncbi.nlm.nih.gov/36017548/David Jiménez, Javier de Miguel-Díez, Ricardo Guijarro...
https://pubmed.ncbi.nlm.nih.gov/26791063/Laura Franco, Cecilia Becattini, Jan Beyer-Westendorf...
https://pubmed.ncbi.nlm.nih.gov/32767653/John A Heit
https://pubmed.ncbi.nlm.nih.gov/18296591/Simone Vanni, Lorenzo Pelagatti, Cosimo Caviglioli...
https://pubmed.ncbi.nlm.nih.gov/41135774/S Z Goldhaber, L Visani, M De Rosa
https://pubmed.ncbi.nlm.nih.gov/10227218/Stefano Barco, Seyed Hamidreza Mahmoudpour, Luca Valerio...
https://pubmed.ncbi.nlm.nih.gov/31615719/Stavros V Konstantinides, Guy Meyer, Cecilia Becattini...
https://pubmed.ncbi.nlm.nih.gov/31504429/Azienda Ospedaliero-Universitaria Careggi
Lead Sponsor
University of Florence
Collaborating Sponsor